ESPERION THERAPEUTICS INC. - COMMON STOCK

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

07 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

04 Nov 2024 07:00:25 By Nasdaq GlobeNewswire

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

31 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Esperion to Report Third Quarter 2024 Financial Results on November 7

24 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid

02 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

25 Sep 2024 15:30:00 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

05 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

03 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

26 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

12 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

07 Aug 2024 15:30:00 By Nasdaq GlobeNewswire

Esperion to Report Second Quarter 2024 Financial Results on August 12

25 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming BTIG Biotech Conference

24 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

16 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

28 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming June Investor Conferences

23 May 2024 08:00:00 By Nasdaq GlobeNewswire

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

22 May 2024 07:00:00 By Nasdaq GlobeNewswire

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

20 May 2024 05:00:00 By Nasdaq GlobeNewswire

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®

14 May 2024 07:00:00 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

10 May 2024 15:00:00 By Nasdaq GlobeNewswire